Clarivate Divests Life Sciences Segment, Elevating Focus on IP and Academic Growth
Clarivate's LS&H divestiture, completed early in Q3 2026, coincides with improved organic recurring revenue growth. The company updated its financial outlook to reflect the effect of this divestiture and its reduced leverage profile.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed